Naptumomab estafenatox

Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma[1] and renal cell carcinoma.[2]

Naptumomab estafenatox
Schematic image of naptumomab estafenatox.

VH, VL: variable (antigen binding) domains of antibody fragment
CH1, CL: constant domains of antibody fragment

SAg: superantigen SEA/E-120
Monoclonal antibody
TypeFab fragment
SourceMouse
Target5T4
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC3255H5025N855O1050S18
Molar mass73513.02 g·mol−1
 NY (what is this?)  (verify)

Mechanism of action

Chemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody with the superantigen staphylococcal enterotoxin A (SEA/E-120, "estafenatox").[3] The Fab binds to 5T4, an antigen expressed by various tumor cells, and the superantigen induces an immune response by activating T lymphocytes.[4]

gollark: Yes, that.
gollark: Well, first, you sacrifice your soul to Ba'hawejodfp, god of hardware design languages and books over 700 pages (gods nowadays have to take on multiple jobs to remain relevant).
gollark: Low-end FPGAs aren't *that* expensive nowadays, are they?
gollark: Why not a Brain[REDACTED] FPGA?
gollark: * direct Haskell conversion and reliance on whatever dark sorcery GHC is up to

See also

References

  1. Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, et al. (September 2009). "Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer". Journal of Clinical Oncology. 27 (25): 4116–23. doi:10.1200/JCO.2008.20.2515. PMC 2734423. PMID 19636016.
  2. Clinical trial number NCT00420888 for "ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma" at ClinicalTrials.gov
  3. "Naptumomabum estafenatoxum" (PDF). WHO Drug Information. 20 (4): 291. 2006. Archived from the original (PDF) on 2011-02-01.
  4. Eisen T, Hedlund G, Forsberg G, Hawkins R (February 2014). "Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin". Current Oncology Reports. 16 (2): 370. doi:10.1007/s11912-013-0370-0. PMC 3918406. PMID 24445502.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.